BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 34706126)

  • 41. Expression of co-inhibitory molecules B7-H4 and B7-H1 in Epstein-Barr virus positive diffuse large B-cell lymphoma and their roles in tumor invasion.
    Jiang Y; Lin J; Zhang J; Lu S; Wang C; Tong Y
    Pathol Res Pract; 2019 Dec; 215(12):152684. PubMed ID: 31679792
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.
    Kataoka K; Miyoshi H; Sakata S; Dobashi A; Couronné L; Kogure Y; Sato Y; Nishida K; Gion Y; Shiraishi Y; Tanaka H; Chiba K; Watatani Y; Kakiuchi N; Shiozawa Y; Yoshizato T; Yoshida K; Makishima H; Sanada M; Onozawa M; Teshima T; Yoshiki Y; Ishida T; Suzuki K; Shimada K; Tomita A; Kato M; Ota Y; Izutsu K; Demachi-Okamura A; Akatsuka Y; Miyano S; Yoshino T; Gaulard P; Hermine O; Takeuchi K; Ohshima K; Ogawa S
    Leukemia; 2019 Jul; 33(7):1687-1699. PubMed ID: 30683910
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinicopathological analysis of neoplastic PD-L1-positive EBV
    Takahara T; Satou A; Ishikawa E; Kohno K; Kato S; Suzuki Y; Takahashi E; Ohashi A; Asano N; Tsuzuki T; Nakamura S
    Virchows Arch; 2021 Mar; 478(3):541-552. PubMed ID: 32803453
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone.
    Rajnai H; Heyning FH; Koens L; Sebestyén A; Andrikovics H; Hogendoorn PC; Matolcsy A; Szepesi Á
    Virchows Arch; 2014 Feb; 464(2):229-39. PubMed ID: 24306958
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A20 (TNFAIP3) deletion in Epstein-Barr virus-associated lymphoproliferative disorders/lymphomas.
    Ando M; Sato Y; Takata K; Nomoto J; Nakamura S; Ohshima K; Takeuchi T; Orita Y; Kobayashi Y; Yoshino T
    PLoS One; 2013; 8(2):e56741. PubMed ID: 23418597
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma.
    Kamper P; Bendix K; Hamilton-Dutoit S; Honoré B; Nyengaard JR; d'Amore F
    Haematologica; 2011 Feb; 96(2):269-76. PubMed ID: 21071500
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diffuse large B-cell lymphoma-derived exosomes push macrophage polarization toward M2 phenotype via GP130/STAT3 signaling pathway.
    Ling HY; Yang Z; Wang PJ; Sun Y; Ju SG; Li J; Fu JX
    Chem Biol Interact; 2022 Jan; 352():109779. PubMed ID: 34922904
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The prognostic significance of EBV DNA load and EBER status in diagnostic specimens from diffuse large B-cell lymphoma patients.
    Okamoto A; Yanada M; Inaguma Y; Tokuda M; Morishima S; Kanie T; Yamamoto Y; Mizuta S; Akatsuka Y; Yoshikawa T; Mizoguchi Y; Nakamura S; Okamoto M; Emi N
    Hematol Oncol; 2017 Mar; 35(1):87-93. PubMed ID: 26177728
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma.
    Park S; Lee J; Ko YH; Han A; Jun HJ; Lee SC; Hwang IG; Park YH; Ahn JS; Jung CW; Kim K; Ahn YC; Kang WK; Park K; Kim WS
    Blood; 2007 Aug; 110(3):972-8. PubMed ID: 17400912
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epstein-Barr virus genome in non-Hodgkin's lymphomas occurring in immunocompetent patients: highest prevalence in nonlymphoblastic T-cell lymphoma and correlation with a poor prognosis. Danish Lymphoma Study Group, LYFO.
    d'Amore F; Johansen P; Houmand A; Weisenburger DD; Mortensen LS
    Blood; 1996 Feb; 87(3):1045-55. PubMed ID: 8562929
    [TBL] [Abstract][Full Text] [Related]  

  • 51. pSTAT3 and MYC in Epstein-Barr virus-positive diffuse large B-cell lymphoma.
    Teoh SH; Khoo JJ; Abdul Salam DSD; Peh SC; Cheah SC
    Malays J Pathol; 2019 Dec; 41(3):273-281. PubMed ID: 31901912
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epstein-Barr virus-negative diffuse large B-cell lymphoma hosts intra- and peritumoral B-cells with activated Epstein-Barr virus.
    Stuhlmann-Laeisz C; Szczepanowski M; Borchert A; Brüggemann M; Klapper W
    Virchows Arch; 2015 Jan; 466(1):85-92. PubMed ID: 25339301
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic role of tumour-associated macrophages and regulatory T cells in EBV-positive and EBV-negative nasopharyngeal carcinoma.
    Ooft ML; van Ipenburg JA; Sanders ME; Kranendonk M; Hofland I; de Bree R; Koljenović S; Willems SM
    J Clin Pathol; 2018 Mar; 71(3):267-274. PubMed ID: 28877959
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
    Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
    Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
    [TBL] [Abstract][Full Text] [Related]  

  • 55. EBV-positive diffuse large B-cell lymphoma features PD-L1 protein but not mRNA overexpression.
    Xue T; Wang WG; Zhou XY; Li XQ
    Pathology; 2018 Dec; 50(7):725-729. PubMed ID: 30389217
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased T-cell responses to Epstein-Barr virus with high viral load in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma.
    Morishima S; Nakamura S; Yamamoto K; Miyauchi H; Kagami Y; Kinoshita T; Onoda H; Yatabe Y; Ito M; Miyamura K; Nagai H; Moritani S; Sugiura I; Tsushita K; Mihara H; Ohbayashi K; Iba S; Emi N; Okamoto M; Iwata S; Kimura H; Kuzushima K; Morishima Y
    Leuk Lymphoma; 2015 Apr; 56(4):1072-8. PubMed ID: 24975317
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
    Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
    Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
    Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
    Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
    [TBL] [Abstract][Full Text] [Related]  

  • 59. International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma.
    Mu S; Shi D; Ai L; Fan F; Peng F; Sun C; Hu Y
    Front Immunol; 2021; 12():732006. PubMed ID: 34745101
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intratumoral FOXP3+ Regulatory T Cells in Diffuse Large B-Cell Lymphoma.
    Serag El-Dien MM; Abdou AG; Asaad NY; Abd El-Wahed MM; Kora MAEM
    Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):534-542. PubMed ID: 26862953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.